Myrexis, Inc. MYRX,
a biotechnology company focused on the development of small molecule
therapeutics, today announced that its Board of Directors has retained Stifel
Nicolaus Weisel, an investment banking firm, to assist it in reviewing and
evaluating a full range of strategic alternatives available to the Company to
enhance shareholder value.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in